The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma
NCT ID: NCT00644254
Last Updated: 2009-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
145 participants
OBSERVATIONAL
2007-10-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
NCT00495924
Pancreatic Cancer Recurrence in the Netherlands
NCT04605237
Treatment of Liver Metastases With Electrochemotherapy
NCT01264952
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
NCT04245410
Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy
NCT06135649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ECLNI is defined as metastatic adenocarcinoma extending through the nodal capsule into the perinodal fatty tissue.
Observers: 1 experienced board-certified GI pathologist, blinded for follow-up results.
Follow-up data are obtained by reviewing patients charts and by a telephone survey of the patient's GP/gastroenterologist in November 2007.
Statistical analysis:
* Common closing date: 1/11/2007
* Kaplan-Meier survival analysis (Log-Rank, Wilcoxon)
* Cox logistic regression (uni/multivariate)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resected DPAC
145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
Pancreatic resection
PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pancreatic resection
PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary resection
Exclusion Criteria
* non DPAC, other tumor
* Postoperative mortality
* Neoadjuvant chemo/radiotherapy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agentschap voor Innovatie door Wetenschap en Technologie
OTHER
KU Leuven
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baki Topal, MD, PhD
Role: STUDY_DIRECTOR
Catholic University Leuven (KULeuven), Belgium
Gregory Sergeant, MD
Role: PRINCIPAL_INVESTIGATOR
Catholic University Leuven, Belgium
Nadine Ectors, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Catholic University Leuven, Belgium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Abdominal Surgery
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECLNI DPAC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.